Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119)

NCT02555657 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

622

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Triple Negative Breast Cancer

Interventions

BIOLOGICAL: pembrolizumab
DRUG: capecitabine
DRUG: eribulin
DRUG: gemcitabine
DRUG: vinorelbine

Sponsor

Merck Sharp & Dohme LLC